| SARS-CoV-2 negative group (N = 339) | COVID-19 patients (N = 270) | OR [95% CI]a | P-Value |
---|---|---|---|---|
rs1800795 Codominant | Â | Â | Â | Â |
 G/G | 249 (73.5) | 204 (75.5) | Reference |  |
 G/C | 80 (23.6) | 58 (21.5) | 0.94 [0.63–1.41] | 0.95 |
 C/C | 10 (2.9) | 8 (3.0) | 0.90 [0.34–2.41] |  |
Recessive model, n (%) | Â | Â | Â | Â |
 G/G + G/C | 329 (97.0) | 262 (97.0) | Reference | – |
 C/C | 10 (3.0) | 8 (3.0) | 0.91 [0.34–2.43] | 0.85 |
Dominant model, n (%) | Â | Â | Â | Â |
 G/G | 249 (73.4) | 204 (75.6) | Reference | – |
 G/C + C/C | 90 (26.6) | 66 (24.4) | 0.94 [0.64–1.38] | 0.75 |
Overdominant model, n (%) | Â | Â | Â | Â |
 G/G + C/C | 259 (76.4) | 212 (78.5) | Reference |  |
 G/C | 80 (23.6) | 58 (21.5) | 0.95 [0.63–1.42] | 0.79 |
Alleles frequencies ± SD |  |  |  |  |
 G | 0.85 ± 0.01 | 0.86 ± 0.02 | Reference | – |
 C | 0.15 ± 0.01 | 0.14 ± 0.02 | 0.92 [0.66–1.27] | 0.60 |
rs1800797 | Â | Â | Â | Â |
 G/G | 255 (75.2) | 203 (75.2) | Reference | – |
 A/G | 75 (22.1) | 59 (21.8) | 1.09 [0.73–1.64] | 0.86 |
 A/A | 9 (2.7) | 8 (3.0) | 0.84 [0.31–2.31] |  |
Recessive model, n (%) | Â | Â | Â | Â |
 A/G + G/G | 330 (97.3) | 262 (97.0) | Reference | – |
 A/A | 9 (2.7) | 8 (3.0) | 0.83 [0.30–2.26] | 0.71 |
Dominant model, n (%) | Â | Â | Â | Â |
 G/G | 255 (75.2) | 203 (75.2) | Reference | – |
 A/A + A/G | 84 (24.8) | 67 (24.8) | 1.06 [0.72–1.56] | 0.78 |
Overdominant model, n (%) | Â | Â | Â | Â |
 G/G + A/A | 264 (77.9) | 211 (78.2) | Reference |  |
 A/G | 75 (22.1) | 59 (21.8) | 1.10 [0.73–1.64] | 0.66 |
Alleles frequencies ± SD |  |  |  |  |
 G | 0.86 ± 0.01 | 0.86 ± 0.02 | Reference | – |
 A | 0.14 ± 0.01 | 0.14 ± 0.02 | 1.02 [0.73–1.41] | 0.93 |